-
1
-
-
84872967522
-
Cancer statistics, 2013
-
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30.
-
(2013)
CA Cancer J Clin
, vol.63
, Issue.1
, pp. 11-30
-
-
Siegel, R.1
Naishadham, D.2
Jemal, A.3
-
2
-
-
0028072991
-
Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma
-
Herman JG, Latif F, Weng Y, et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A. 1994;91(21):9700–9704.
-
(1994)
Proc Natl Acad Sci U S A
, vol.91
, Issue.21
, pp. 9700-9704
-
-
Herman, J.G.1
Latif, F.2
Weng, Y.3
-
4
-
-
54549113030
-
The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer
-
2sensing and cancer. Nat Rev Cancer. 2008;8(11):865–873.
-
(2008)
Nat Rev Cancer
, vol.8
, Issue.11
, pp. 865-873
-
-
Kaelin, W.G.1
-
5
-
-
84859372195
-
EGFR protein overexpression correlates with chromosome 7 polysomy and poor prognostic parameters in clear cell renal cell carcinoma
-
Dorđević G, Matušan Ilijaš K, Hadžisejdić I, Maričić A, Grahovac B, Jonjić N. EGFR protein overexpression correlates with chromosome 7 polysomy and poor prognostic parameters in clear cell renal cell carcinoma. J Biomed Sci. 2012;19:40.
-
(2012)
J Biomed Sci
, vol.19
-
-
Dorđević, G.1
Matušan Ilijaš, K.2
Hadžisejdić, I.3
Maričić, A.4
Grahovac, B.5
Jonjić, N.6
-
6
-
-
77952545672
-
TP53, EGFR, and KRAS mutations in relation to VHL inactivation and lifestyle risk factors in renal-cell carcinoma from central and eastern Europe
-
Szymańska K, Moore LE, Rothman N, et al. TP53, EGFR, and KRAS mutations in relation to VHL inactivation and lifestyle risk factors in renal-cell carcinoma from central and eastern Europe. Cancer Lett. 2010;293(1):92–98.
-
(2010)
Cancer Lett
, vol.293
, Issue.1
, pp. 92-98
-
-
Szymańska, K.1
Moore, L.E.2
Rothman, N.3
-
7
-
-
4043171462
-
Upstream and downstream of mTOR
-
Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 2004;18(16):1926–1945.
-
(2004)
Genes Dev
, vol.18
, Issue.16
, pp. 1926-1945
-
-
Hay, N.1
Sonenberg, N.2
-
8
-
-
84921776079
-
RNA-seq reveals aurora kinase-driven mTOR Pathway activation in patients with sarcomatoid metastatic renal cell carcinoma
-
Pal SK, He M, Tong T, et al. RNA-seq reveals aurora kinase-driven mTOR Pathway activation in patients with sarcomatoid metastatic renal cell carcinoma. Mol Cancer Res. 2015;13(1):130–137.
-
(2015)
Mol Cancer Res
, vol.13
, Issue.1
, pp. 130-137
-
-
Pal, S.K.1
He, M.2
Tong, T.3
-
9
-
-
84907468719
-
MTOR inhibition induces compensatory, therapeutically targetable MEK activation in renal cell carcinoma
-
Bailey ST, Zhou B, Damrauer JS, et al. mTOR inhibition induces compensatory, therapeutically targetable MEK activation in renal cell carcinoma. PloS One. 2014;9(9):e104413.
-
(2014)
Plos One
, vol.9
, Issue.9
-
-
Bailey, S.T.1
Zhou, B.2
Damrauer, J.S.3
-
10
-
-
84892915652
-
Circadian regulation of mTOR by the ubiquitin pathway in renal cell carcinoma
-
Okazaki H, Matsunaga N, Fujioka T, et al. Circadian regulation of mTOR by the ubiquitin pathway in renal cell carcinoma. Cancer Res. 2014;74(2):543–551.
-
(2014)
Cancer Res
, vol.74
, Issue.2
, pp. 543-551
-
-
Okazaki, H.1
Matsunaga, N.2
Fujioka, T.3
-
11
-
-
34347220473
-
Defining the role of mTOR in cancer
-
Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell. 2007;12(1):9–22.
-
(2007)
Cancer Cell
, vol.12
, Issue.1
, pp. 9-22
-
-
Guertin, D.A.1
Sabatini, D.M.2
-
12
-
-
84855322629
-
MTOR activates hypoxia-inducible factor-1α and inhibits neuronal apoptosis in the developing rat brain during the early phase after hypoxia-ischemia
-
Chen H, Xiong T, Qu Y, Zhao F, Ferriero D, Mu D. mTOR activates hypoxia-inducible factor-1α and inhibits neuronal apoptosis in the developing rat brain during the early phase after hypoxia-ischemia. Neurosci Lett. 2012;507(2):118–123.
-
(2012)
Neurosci Lett
, vol.507
, Issue.2
, pp. 118-123
-
-
Chen, H.1
Xiong, T.2
Qu, Y.3
Zhao, F.4
Ferriero, D.5
Mu, D.6
-
13
-
-
34547134517
-
Hypoxia-inducible factor 1α is regulated by the mammalian target of rapamycin (MTOR) via an mTOR signaling motif
-
Land SC, Tee AR. Hypoxia-inducible factor 1α is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif. J Biol Chem. 2007;282(28):20534–20543.
-
(2007)
J Biol Chem
, vol.282
, Issue.28
, pp. 20534-20543
-
-
Land, S.C.1
Tee, A.R.2
-
14
-
-
30044432434
-
Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer
-
Thomas GV, Tran C, Mellinghoff IK, et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med. 2006;12(1):122–127.
-
(2006)
Nat Med
, vol.12
, Issue.1
, pp. 122-127
-
-
Thomas, G.V.1
Tran, C.2
Mellinghoff, I.K.3
-
15
-
-
84865856500
-
Dual PI3K/mTOR inhibitor NVP-BEZ235 suppresses hypoxia-inducible factor (HIF)-1α expression by blocking protein translation and increases cell death under hypoxia
-
Karar J, Cerniglia GJ, Lindsten T, Koumenis C, Maity A. Dual PI3K/mTOR inhibitor NVP-BEZ235 suppresses hypoxia-inducible factor (HIF)-1α expression by blocking protein translation and increases cell death under hypoxia. Cancer Biol Ther. 2012;13(11):1102–1111.
-
(2012)
Cancer Biol Ther
, vol.13
, Issue.11
, pp. 1102-1111
-
-
Karar, J.1
Cerniglia, G.J.2
Lindsten, T.3
Koumenis, C.4
Maity, A.5
-
16
-
-
84899538303
-
Prolonged efficacy of mTOR inhibitors in papillary renal cell carcinoma: Progression-free survival lasting for over 3 years, a case report and review of the literature
-
Daste A, Gross-Goupil M, Roca S, Bernhard JC, Ravaud A. Prolonged efficacy of mTOR inhibitors in papillary renal cell carcinoma: progression-free survival lasting for over 3 years, a case report and review of the literature. Target Oncol. 2014;9(1):81–84.
-
(2014)
Target Oncol
, vol.9
, Issue.1
, pp. 81-84
-
-
Daste, A.1
Gross-Goupil, M.2
Roca, S.3
Bernhard, J.C.4
Ravaud, A.5
-
17
-
-
84898011066
-
Role of natural and adaptive immunity in renal cell carcinoma response to VEGFR-TKIs and mTOR inhibitor
-
Santoni M, Berardi R, Amantini C, et al. Role of natural and adaptive immunity in renal cell carcinoma response to VEGFR-TKIs and mTOR inhibitor. Int J Cancer. 2014;134(12):2772–2777.
-
(2014)
Int J Cancer
, vol.134
, Issue.12
, pp. 2772-2777
-
-
Santoni, M.1
Berardi, R.2
Amantini, C.3
-
18
-
-
0842304369
-
Mammalian target of rapamycin inhibition as therapy for hematologic malignancies
-
Panwalkar A, Verstovsek S, Giles FJ. Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. Cancer. 2004;100(4):657–666.
-
(2004)
Cancer
, vol.100
, Issue.4
, pp. 657-666
-
-
Panwalkar, A.1
Verstovsek, S.2
Giles, F.J.3
-
19
-
-
65549167833
-
Targeting the mTOR signaling network for cancer therapy
-
Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy. J Clin Oncol. 2009;27(13):2278–2287.
-
(2009)
J Clin Oncol
, vol.27
, Issue.13
, pp. 2278-2287
-
-
Meric-Bernstam, F.1
Gonzalez-Angulo, A.M.2
-
20
-
-
0041802820
-
Targeting mTOR signaling for cancer therapy
-
Huang S, Houghton PJ. Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol. 2003;3(4):371–377.
-
(2003)
Curr Opin Pharmacol
, vol.3
, Issue.4
, pp. 371-377
-
-
Huang, S.1
Houghton, P.J.2
-
21
-
-
1542398693
-
Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma
-
Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol. 2004;22(5):909–918.
-
(2004)
J Clin Oncol
, vol.22
, Issue.5
, pp. 909-918
-
-
Atkins, M.B.1
Hidalgo, M.2
Stadler, W.M.3
-
22
-
-
1542327671
-
Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs
-
Mohi MG, Boulton C, Gu TL, et al. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc Natl Acad Sci U S A. 2004;101(9):3130–3135.
-
(2004)
Proc Natl Acad Sci U S A
, vol.101
, Issue.9
, pp. 3130-3135
-
-
Mohi, M.G.1
Boulton, C.2
Gu, T.L.3
-
23
-
-
6044259204
-
Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells
-
Mondesire WH, Jian W, Zhang H, et al. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res. 2004;10(20):7031–7042.
-
(2004)
Clin Cancer Res
, vol.10
, Issue.20
, pp. 7031-7042
-
-
Mondesire, W.H.1
Jian, W.2
Zhang, H.3
-
24
-
-
84880489175
-
Targeting mTOR to overcome epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer cells
-
Fei SJ, Zhang XC, Dong S, et al. Targeting mTOR to overcome epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer cells. PloS One. 2013;8(7):e69104.
-
(2013)
Plos One
, vol.8
, Issue.7
-
-
Fei, S.J.1
Zhang, X.C.2
Dong, S.3
-
25
-
-
84883328678
-
Transglutaminase 2 inhibition found to induce p53 mediated apoptosis in renal cell carcinoma
-
Ku BM, Kim DS, Kim KH, et al. Transglutaminase 2 inhibition found to induce p53 mediated apoptosis in renal cell carcinoma. FASEB J. 2013;27(9):3487–3495.
-
(2013)
FASEB J
, vol.27
, Issue.9
, pp. 3487-3495
-
-
Ku, B.M.1
Kim, D.S.2
Kim, K.H.3
-
26
-
-
14644428498
-
The relationship of expression of Bcl-2, p53, and proliferating cell nuclear antigen (PCNA) to cell proliferation and apoptosis in renal cell carcinoma
-
Zhu Z, Xing S, Cheng P, et al. The relationship of expression of Bcl-2, p53, and proliferating cell nuclear antigen (PCNA) to cell proliferation and apoptosis in renal cell carcinoma. J Huazhong Univ Sci Technolog Med Sci. 2004;24(4):354–357.
-
(2004)
J Huazhong Univ Sci Technolog Med Sci
, vol.24
, Issue.4
, pp. 354-357
-
-
Zhu, Z.1
Xing, S.2
Cheng, P.3
-
27
-
-
0031907378
-
P53 Modulation of Fas/Apo-1 mediated apoptosis in a human renal cell carcinoma cell line
-
Miyake H, Hara I, Gohji K, Arakawa S, Kamidono S. p53 Modulation of Fas/Apo-1 mediated apoptosis in a human renal cell carcinoma cell line. Int J Oncol. 1998;12(2):469–473.
-
(1998)
Int J Oncol
, vol.12
, Issue.2
, pp. 469-473
-
-
Miyake, H.1
Hara, I.2
Gohji, K.3
Arakawa, S.4
Kamidono, S.5
-
28
-
-
0034704923
-
The loss of mdm2 induces p53-mediated apoptosis
-
de Rozieres S, Maya R, Oren M, Lozano G. The loss of mdm2 induces p53-mediated apoptosis. Oncogene. 2000;19(13):1691–1697.
-
(2000)
Oncogene
, vol.19
, Issue.13
, pp. 1691-1697
-
-
De Rozieres, S.1
Maya, R.2
Oren, M.3
Lozano, G.4
-
29
-
-
0032185124
-
Kung AL, et al. P300/MDM2 complexes participate in MDM2-mediated p53 degradation
-
Grossman SR, Perez M, Kung AL, et al. p300/MDM2 complexes participate in MDM2-mediated p53 degradation. Mol Cell. 1998;2(4):405–415.
-
(1998)
Mol Cell
, vol.2
, Issue.4
, pp. 405-415
-
-
Grossman, S.R.1
Perez, M.2
-
30
-
-
0026649648
-
The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation
-
Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 1992;69(7):1237–1245.
-
(1992)
Cell
, vol.69
, Issue.7
, pp. 1237-1245
-
-
Momand, J.1
Zambetti, G.P.2
Olson, D.C.3
George, D.4
Levine, A.J.5
-
31
-
-
0027325132
-
Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53
-
Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature. 1993;362(6423):857–860.
-
(1993)
Nature
, vol.362
, Issue.6423
, pp. 857-860
-
-
Oliner, J.D.1
Pietenpol, J.A.2
Thiagalingam, S.3
Gyuris, J.4
Kinzler, K.W.5
Vogelstein, B.6
-
32
-
-
78049305999
-
MDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53-mutated mantle cell lymphoma
-
Jin L, Tabe Y, Kojima K, et al. MDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53-mutated mantle cell lymphoma. Cancer Lett. 2010;299(2):161–170.
-
(2010)
Cancer Lett
, vol.299
, Issue.2
, pp. 161-170
-
-
Jin, L.1
Tabe, Y.2
Kojima, K.3
-
33
-
-
84873082565
-
Induction of apoptosis in non-small cell lung cancer by downregulation of MDM2 using pH-responsive PMPC-b-PDPA/siRNA complex nanoparticles
-
Yu H, Zou Y, Jiang L, et al. Induction of apoptosis in non-small cell lung cancer by downregulation of MDM2 using pH-responsive PMPC-b-PDPA/siRNA complex nanoparticles. Biomaterials. 2013;34(11):2738–2747.
-
(2013)
Biomaterials
, vol.34
, Issue.11
, pp. 2738-2747
-
-
Yu, H.1
Zou, Y.2
Jiang, L.3
-
34
-
-
84873079604
-
Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells
-
Mir R, Tortosa A, Martinez-Soler F, et al. Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells. Int J Cancer. 2013;132(7):1525–1536.
-
(2013)
Int J Cancer
, vol.132
, Issue.7
, pp. 1525-1536
-
-
Mir, R.1
Tortosa, A.2
Martinez-Soler, F.3
-
35
-
-
79960087105
-
The suppression of prostate LNCaP cancer cells growth by selenium nanoparticles through Akt/Mdm2/AR controlled apoptosis
-
Kong L, Yuan Q, Zhu H, et al. The suppression of prostate LNCaP cancer cells growth by selenium nanoparticles through Akt/Mdm2/AR controlled apoptosis. Biomaterials. 2011;32(27):6515–6522.
-
(2011)
Biomaterials
, vol.32
, Issue.27
, pp. 6515-6522
-
-
Kong, L.1
Yuan, Q.2
Zhu, H.3
-
36
-
-
76249112073
-
P53 and MDM2 in renal cell carcinoma: Biomarkers for disease progression and future therapeutic targets?
-
Noon AP, Vlatkovic N, Polanski R, et al. P53 and MDM2 in renal cell carcinoma: biomarkers for disease progression and future therapeutic targets? Cancer. 2010;116(4):780–790.
-
(2010)
Cancer
, vol.116
, Issue.4
, pp. 780-790
-
-
Noon, A.P.1
Vlatkovic, N.2
Polanski, R.3
-
37
-
-
0036129145
-
Clinical significance of p53, mdm2, and Bcl-2 proteins in renal cell carcinoma
-
Uchida T, Gao JP, Wang C, et al. Clinical significance of p53, mdm2, and Bcl-2 proteins in renal cell carcinoma. Urology. 2002;59(4): 615–620.
-
(2002)
Urology
, vol.59
, Issue.4
, pp. 615-620
-
-
Uchida, T.1
Gao, J.P.2
Wang, C.3
-
38
-
-
0034026143
-
Mdm2 expression as a prognostic indicator in clear cell renal cell carcinoma: Comparison with p53 overexpression and clinicopathological parameters
-
Haitel A, Wiener HG, Baethge U, Marberger M, Susani M. Mdm2 expression as a prognostic indicator in clear cell renal cell carcinoma: comparison with p53 overexpression and clinicopathological parameters. Clin Cancer Res. 2000;6(5):1840–1844.
-
(2000)
Clin Cancer Res
, vol.6
, Issue.5
, pp. 1840-1844
-
-
Haitel, A.1
Wiener, H.G.2
Baethge, U.3
Marberger, M.4
Susani, M.5
-
39
-
-
51649098950
-
The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML
-
Kojima K, Shimanuki M, Shikami M, et al. The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML. Leukemia. 2008;22(9):1728–1736.
-
(2008)
Leukemia
, vol.22
, Issue.9
, pp. 1728-1736
-
-
Kojima, K.1
Shimanuki, M.2
Shikami, M.3
-
40
-
-
72549094296
-
An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals
-
Mohammad RM, Wu J, Azmi AS, et al. An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals. Mol Cancer. 2009;8:115.
-
(2009)
Mol Cancer
, vol.8
-
-
Mohammad, R.M.1
Wu, J.2
Azmi, A.S.3
-
41
-
-
34547220487
-
MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma
-
Hirata H, Hinoda Y, Kikuno N, et al. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma. Clin Cancer Res. 2007;13(14):4123–4129.
-
(2007)
Clin Cancer Res
, vol.13
, Issue.14
, pp. 4123-4129
-
-
Hirata, H.1
Hinoda, Y.2
Kikuno, N.3
-
42
-
-
33748254960
-
Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas
-
Lin F, Zhang PL, Yang XJ, Prichard JW, Lun M, Brown RE. Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas. Ann Clin Lab Sci. 2006;36(3):283–293.
-
(2006)
Ann Clin Lab Sci
, vol.36
, Issue.3
, pp. 283-293
-
-
Lin, F.1
Zhang, P.L.2
Yang, X.J.3
Prichard, J.W.4
Lun, M.5
Brown, R.E.6
-
43
-
-
84911387339
-
Fulda S. Synthetic lethality by co-targeting mitochondrial apoptosis and PI3K/Akt/mTOR signaling
-
Fulda S. Synthetic lethality by co-targeting mitochondrial apoptosis and PI3K/Akt/mTOR signaling. Mitochondrion. 2014;19 Pt A:85–87.
-
(2014)
Mitochondrion
, vol.19
, pp. 85-87
-
-
-
44
-
-
0034145215
-
Role of HIF-1 as a transcription factor involved in embryonic development, cancer progression and apoptosis (Review)
-
Minet E, Michel G, Remacle J, Michiels C. Role of HIF-1 as a transcription factor involved in embryonic development, cancer progression and apoptosis (review). Int J Mol Med. 2000;5(3):253–259.
-
(2000)
Int J Mol Med
, vol.5
, Issue.3
, pp. 253-259
-
-
Minet, E.1
Michel, G.2
Remacle, J.3
Michiels, C.4
-
45
-
-
71549134278
-
Rapamycin increases the p53/MDM2 protein ratio and p53-dependent apoptosis by translational inhibition of mdm2 in cancer cells
-
Kao CL, Hsu HS, Chen HW, Cheng TH. Rapamycin increases the p53/MDM2 protein ratio and p53-dependent apoptosis by translational inhibition of mdm2 in cancer cells. Cancer Lett. 2009;286(2):250–259.
-
(2009)
Cancer Lett
, vol.286
, Issue.2
, pp. 250-259
-
-
Kao, C.L.1
Hsu, H.S.2
Chen, H.W.3
Cheng, T.H.4
-
46
-
-
20444363122
-
The coordinate regulation of the p53 and mTOR pathways in cells
-
Feng Z, Zhang H, Levine AJ, Jin S. The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci U S A. 2005;102(23):8204–8209.
-
(2005)
Proc Natl Acad Sci U S A
, vol.102
, Issue.23
, pp. 8204-8209
-
-
Feng, Z.1
Zhang, H.2
Levine, A.J.3
Jin, S.4
-
47
-
-
77954310492
-
The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein
-
Feng Z, Levine AJ. The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein. Trends Cell Biol. 2010;20(7):427–434.
-
(2010)
Trends Cell Biol
, vol.20
, Issue.7
, pp. 427-434
-
-
Feng, Z.1
Levine, A.J.2
-
48
-
-
84925659251
-
Preclinical evaluation of the mTOR inhibitor, temsirolimus, in combination with the epothilone B analog, ixabepilone in renal cell carcinoma
-
von Roemeling CA, Marlow LA, Kennedy WP, Kennedy GT, Copland JA, Menefee ME. Preclinical evaluation of the mTOR inhibitor, temsirolimus, in combination with the epothilone B analog, ixabepilone in renal cell carcinoma. Am J Cancer Res. 2013;3(4):390–401.
-
(2013)
Am J Cancer Res
, vol.3
, Issue.4
, pp. 390-401
-
-
Von Roemeling, C.A.1
Marlow, L.A.2
Kennedy, W.P.3
Kennedy, G.T.4
Copland, J.A.5
Menefee, M.E.6
-
49
-
-
79960683561
-
Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib
-
Roulin D, Waselle L, Dormond-Meuwly A, Dufour M, Demartines N, Dormond O. Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib. Mol Cancer. 2011;10:90.
-
(2011)
Mol Cancer
, vol.10
-
-
Roulin, D.1
Waselle, L.2
Dormond-Meuwly, A.3
Dufour, M.4
Demartines, N.5
Dormond, O.6
-
50
-
-
84856739876
-
Evaluating rational non-cross-resistant combination therapy in advanced clear cell renal cell carcinoma: Combined mTOR and AKT inhibitor therapy
-
Holland WS, Tepper CG, Pietri JE, et al. Evaluating rational non-cross-resistant combination therapy in advanced clear cell renal cell carcinoma: combined mTOR and AKT inhibitor therapy. Cancer Chemother Pharmacol. 2012;69(1):185–194.
-
(2012)
Cancer Chemother Pharmacol
, vol.69
, Issue.1
, pp. 185-194
-
-
Holland, W.S.1
Tepper, C.G.2
Pietri, J.E.3
-
51
-
-
73649094752
-
PKB/Akt activation inhibits p53-mediated HIF1A degradation that is independent of MDM2
-
Choy MK, Movassagh M, Bennett MR, Foo RS. PKB/Akt activation inhibits p53-mediated HIF1A degradation that is independent of MDM2. J Cell Physiol. 2010;222(3):635–639.
-
(2010)
J Cell Physiol
, vol.222
, Issue.3
, pp. 635-639
-
-
Choy, M.K.1
Movassagh, M.2
Bennett, M.R.3
Foo, R.S.4
-
52
-
-
68849093989
-
Tumour suppression by p53: The importance of apoptosis and cellular senescence
-
Zuckerman V, Wolyniec K, Sionov RV, Haupt S, Haupt Y. Tumour suppression by p53: the importance of apoptosis and cellular senescence. J Pathology. 2009;219(1):3–15.
-
(2009)
J Pathology
, vol.219
, Issue.1
, pp. 3-15
-
-
Zuckerman, V.1
Wolyniec, K.2
Sionov, R.V.3
Haupt, S.4
Haupt, Y.5
-
53
-
-
84894079832
-
Emerging strategies to overcome the resistance to current mTOR inhibitors in renal cell carcinoma
-
Santoni M, Pantano F, Amantini C, et al. Emerging strategies to overcome the resistance to current mTOR inhibitors in renal cell carcinoma. Biochim Biophys Acta. 2014;1845(2):221–231.
-
(2014)
Biochim Biophys Acta
, vol.1845
, Issue.2
, pp. 221-231
-
-
Santoni, M.1
Pantano, F.2
Amantini, C.3
-
54
-
-
22044438985
-
Synergistic growth inhibition by Iressa and rapamycin is modulated by VHL mutations in renal cell carcinoma
-
Gemmill RM, Zhou M, Costa L, Korch C, Bukowski RM, Drabkin HA. Synergistic growth inhibition by Iressa and rapamycin is modulated by VHL mutations in renal cell carcinoma. Br J Cancer. 2005;92(12):2266–2277.
-
(2005)
Br J Cancer
, vol.92
, Issue.12
, pp. 2266-2277
-
-
Gemmill, R.M.1
Zhou, M.2
Costa, L.3
Korch, C.4
Bukowski, R.M.5
Drabkin, H.A.6
-
55
-
-
77951243028
-
Autophagy regulation by p53
-
Maiuri MC, Galluzzi L, Morselli E, Kepp O, Malik SA, Kroemer G. Autophagy regulation by p53. Curr Opin Cell Biol. 2010;22(2):181–185.
-
(2010)
Curr Opin Cell Biol
, vol.22
, Issue.2
, pp. 181-185
-
-
Maiuri, M.C.1
Galluzzi, L.2
Morselli, E.3
Kepp, O.4
Malik, S.A.5
Kroemer, G.6
-
56
-
-
44649141966
-
Regulation of autophagy by cytoplasmic p53
-
Tasdemir E, Maiuri MC, Galluzzi L, et al. Regulation of autophagy by cytoplasmic p53. Nat Cell Biol. 2008;10(6):676–687.
-
(2008)
Nat Cell Biol
, vol.10
, Issue.6
, pp. 676-687
-
-
Tasdemir, E.1
Maiuri, M.C.2
Galluzzi, L.3
|